biostudies-literatureUnknown22(1)Sato KUniversity of Queensland“la Caixa” FoundationWesley Medical ResearchThe Health Research Board of IrelandEuropean Union’s research and innovation programmePrince Charles Hospital FoundationBiomedicine international training research programme for excellent clinician-scientistsWellcome Trust<h4>Background</h4>The influence of renin-angiotensin-aldosterone system (RAAS) inhibitors on the critically ill COVID-19 patients with pre-existing hypertension remains uncertain. This study examined the impact of previous use of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) on the critically ill COVID-19 patients.<h4>Methods</h4>Data from an international, prospective, observational cohort study involving 354 hospitals spanning 54 countries were included. A cohort of 737 COVID-19 patients with pre-existing hypertension admitted to intensive care units (ICUs) in 2020 were targeted. Multi-state survival analysis was performed to evaluate in-hospital mortality and hospital length of stay up to 90 days following ICU admission.<h4>Results</h4>A total BMC cardiovascular disorders123https://www.ebi.ac.uk/biostudies/studies/S-EPMC8942148biostudies-literatureImpact of renin-angiotensin-aldosterone system inhibition on mortality in critically ill COVID-19 patients with pre-existing hypertension: a prospective cohort study.PMC8942148Grasselli GIchiba SMurthy SLaffey JWhite NFanning JPObonyo NOhshimo SFraser JFNg PYArora RCBartlett RWorku ETFan EOgino MHodgson CMay MNichol AChiumello DTorres AElhazmi AAppadurai VMarwali EYang ICiullo ASuen JYLuna CBurrell ACOVID-19 Critical Care Consortium InvestigatorsBrodie DJuzar DABassi GLSato KDip GYamashita MHHelms LDalton HJfalseImpact of renin-angiotensin-aldosterone system inhibition on mortality in critically ill COVID-19 patients with pre-existing hypertension: a prospective cohort study.<h4>Background</h4>The influence of renin-angiotensin-aldosterone system (RAAS) inhibitors on the critically ill COVID-19 patients with pre-existing hypertension remains uncertain. This study examined the impact of previous use of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) on the critically ill COVID-19 patients.<h4>Methods</h4>Data from an international, prospective, observational cohort study involving 354 hospitals spanning 54 countries were included. A cohort of 737 COVID-19 patients with pre-existing hypertension admitted to intensive care units (ICUs) in 2020 were targeted. Multi-state survival analysis was performed to evaluate in-hospital mortality and hospital length of stay up to 90 days following ICU admission.<h4>Results</h4>A total 2022-01-01T00:00:00Z2022 Mar2025-04-04T14:57:14.992Z2024-11-20T05:53:21.706ZS-EPMC89421483532164910.1186/s12872-022-02565-1